40 Background: Acute coronary syndrome (ACS) is a growing global health problem, and 41 precision medicine techniques hold promise for the development of diagnostic indicators of 42 ACS. In this pilot, we sought to assess the utility of an integrated analysis of metabolomic and 43 microRNA data in peripheral blood to distinguish patients with abnormal cardiac stress testing 44 from matched controls.
6 136 tandem mass spectrometry on a Quattro Micro instrument (Waters Corporation, Milford, MA) to 137 analyze acylcarnitines and amino acids. The lower level of quantitation for amino acids was 0.5 138 µM and for acylcarnitines the limit of quantitation was 0.015 µM. 211 
255
For the integrative discriminant analysis, both the baseline model and the stress-delta 256 model produced a single latent component. We calculated error rates for our integrated analysis 257 model for predicting cases or controls. Integrative analysis of metabolite levels and microRNA 258 expression at baseline showed modest performance for distinguishing cases from controls, with 259 an overall error rate of 0.143 (Table 3 ). Using stress-delta data actually led to a worse error 260 (0.500) for distinguishing cases from controls.
261
262 294 which combines exercise tolerance information and electrocardiogram characteristics to make a 295 prediction of future risk. However, these multi-modal stress tests do not take advantage of the 296 large amounts of data that we are currently capable of collecting from patients' blood samples.
297
Although our current modalities of stress testing are sensitive for obstructive coronary disease, 298 their accuracy can be further improved, particularly for identifying specific high-risk phenotypes 299 that benefit from emerging therapies.
301
In contrast to the blood-based biomarker approach for evaluation of acute myocardial 302 infarction, currently assessment for myocardial ischemia and/or obstructive coronary artery is 303 heavily imaging-dependent. Use of serial biomarkers is not routine practice for assessing 304 myocardial ischemia, especially in the context of a stress test. Thus, this study presents a novel 305 paradigm for assessing patients for myocardial ischemia. Our current ability to serially measure 306 multiple blood-based molecules presents an opportunity to develop more sophisticated multi-307 modal stress tests that incorporate large amounts of data.
309
We have previously examined the utility of blood-based biomarkers to enhance cardiac 310 stress testing (19, 21, 22) . In this pilot study, we outline the methodology to further develop a 311 biomarker-augmented stress test using a precision medicine approach. First, we identified 312 several differences at baseline, post-stress, and stress-delta between cases and controls, 313 largely as a consequence of the large number of analytes we assessed. While a great deal of 314 prior literature has examined baseline (resting) biomarkers for prediction of coronary heart 315 disease, stress-delta biomarker assessments give us the ability to assess acute changes in 316 response to a controlled ischemic event, with the benefit of within-patient control for baseline 317 values. We were able to assess a large number of potential biomarkers in each blood sample, 318 creating the possibility of a systems biology approach to biomarker discovery. 
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The dataset(s) supporting the conclusions of this article is(are) included within the article 367 (and its additional file(s)). 
368

374
 Funding: The current study was made possible by funding support via a Pilot Grant from 375 the Emergency Medicine Foundation. Samples were collected in a prior study that was 376 supported by an investigator-initiated grant from Abbott Laboratories. The authors 377 retained possession of all data and decision on whether to publish at all times.
